The story
1996: Established as a direct-to-consumer marketing company with in-house production capacity for infomercials.
1999: Restructures operations, shifting its business model to a vertical platform for the development of personal care and over-the-counter (OTC) medications, establishes a network of distributors and wholesalers to place its products at strategic points of sale. Changes its advertising strategy from infomercials to 10–30 second TV spots.
2003: Begins strengthening organic growth through the development of new brands and products. This year it started selling to pharmaceutical wholesalers.
2004: Nexxus Capital, a Mexican private equity fund manager, acquires 30% of Genomma Lab Internacional. With Nexxus Capital’s entry, Genomma Lab begins institutionalization.
2005: Starts international expansion, with first sales in Peru.
2006: Expands executive team, strengthening operations in Mexico.
2007: Expands product portfolio through new developments and line extensions.
2008: On June 18, 2008, Genomma Lab Internacional announces its Initial Public Offering (IPO) on the Mexican Stock Exchange. In December of that year, operations began in Colombia.
Read the full text
2009: Acquires Medicinas y Medicamentos Nacionales, and brands Jockey Club, Flor de Naranja Sanborns, Teatrical, and Henna Egipcia. Launches generic medicines line Primer Nivel.
2010: Acquires brands Nasalub, Micotex, Ossart, English Leather, Galaflex, Affair, and Santé. Begins operations in Brazil and the United States, expanding its international presence to 14 countries.
2011: Acquires brands Vanart, Pomada de la Campana, Wildroot, Alert, and Nórdiko.
2012: Acquires brands Fermodyl, Zan Zusi, Altiva, Amara, Larizá, Bioskin, and XL-3 in Mexico; Piecidex in Argentina; and Dermaglós in Brazil.
2013: Acquires Tafirol in Argentina and Losec A, Oxigricol, Mopral, Estomacurol, Xyloproct, Xyloderm, Passiflorine, and Ah-Micol in Mexico. Enters the Sustainable IPC Index and Morgan Stanley EM Latin America and Mexico Index.
2015: Begins a turnaround process to strengthen the business model.
2017: Obtains credits from the IFC (World Bank) and IDB Invest (Inter-American Development Bank) to finance the most modern manufacturing plant in Latin America.
2018: Issues debt certificate for 2.45 billion pesos and becomes one of the leading global skincare companies.
From Wikipedia’s article on Genomma Lab Internacional, shared under CC BY-SA 4.0.4